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Objective: The study utilizes meta-regression analysis to quantify the dose-dependent effects of 
statin pharmacotherapy on vasospasm, delayed ischemic neurologic deficits (DINDs) and mortality 
in aneurysmal subarachnoid hemorrhage (aSAH). 
Methods: Prospective, retrospective observational studies and randomized controlled trials (RCTs) 
were retrieved by a systematic database search. Summary estimates were expressed as absolute 
risk (AR) for a given statin dose or control (placebo). Meta-regression using inverse variance 
weighting and robust variance estimation was performed to assess the effect of statin dose on 
transformed AR in a random effects model. Dose-dependence of predicted AR with 95% confidence 
interval (CI) was recovered using Miller’s Freeman-Tukey inverse. 
Results: The database search and study selection criteria yielded 18 studies (2594 patients) for 
analysis. These included twelve RCTs, four retrospective observational studies and two prospective 
observational studies. Twelve studies investigated simvastatin, while the remaining studies 
investigated atorvastatin, pravastatin or pitavastatin, with simvastatin equivalent doses ranging from 
20 mg to 80 mg. Meta-regression revealed dose-dependent reductions in Freeman-Tukey 
transformed absolute risk of vasospasm (slope coefficient -0.00404, 95% CI -0.00720 to -0.00087; p 
= 0.0321), DINDs (slope coefficient -0.00316, 95% CI -0.00586 to -0.00047; p = 0.0392), and 
mortality (slope coefficient -0.00345, 95% CI -0.00623 to -0.00067; p = 0.0352).  
Conclusions: The present meta-regression provides weak evidence for dose-dependent reductions 
in vasospasm, DINDs and mortality associated with acute statin use following aSAH. However, the 
analysis was limited by substantial heterogeneity among individual studies. Higher dosing strategies 















Subarachnoid hemorrhages account for 3% of all strokes[1, 2] and despite improvements in 
outcomes case mortality rates still approach 50%[3]. Intracranial aneurysm rupture is the cause of 
85% of subarachnoid hemorrhages and is nowadays managed with surgical clipping or 
endovascular coiling of the aneurysm to prevent re-rupture and further bleeding. After the initial 
bleed, vasospasm and delayed ischemic neurological deficits (DINDs) are significant contributors to 
long-term morbidity and mortality. Angiographic evidence of vasospasm may be demonstrated in up 
to two-thirds of aneurysmal SAH (aSAH) patients[4]. Vasospasm following aSAH typically occurs 
between 4 to 14 days after ictus, resolving by 21 days. Vasospasm is also associated with and may 
contribute to symptomatic delayed ischemic neurological deficit (DIND), which is seen in 
approximately one third of patients. While various pharmacological approaches for preventing 
vasospasm and DIND have been explored[5], nimodipine remains the only pharmacological 
intervention that has been shown to reduce vasospasm and DIND after SAH[6-8].  
 
Statin therapy is another intervention that has received significant attention but their role in aSAH 
remains uncertain. Experimental animal models have shown reduction of cerebral vasospasm after 
aSAH with simvastatin[9, 10]. Beyond their lipid lowering effects, it is thought that the 
neuroprotective advantages of statins in aSAH arise from their pleiotropic effects. These include 
anti-platelet[11], anti-oxidative[12] and anti-inflammatory effects[13]. Statins also produce cerebral 
vasodilation by increasing endothelial-derived nitric oxide synthase activity[14]. 
 
However, these experimental findings have only been reproduced in human aSAH studies with 
limited success. In a single-institution prospective observational cohort study, McGirt et al.[15] 
compared 170 consecutive patients treated with 80 mg simvastatin against 170 consecutive 
patients in the pre-statin era found no difference in incidence of symptomatic vasospasm (25.3% vs 












ACCEPTED MANUSCRIPTlarge multicenter STASH randomized trial[16], which included 803 patients randomly assigned to 
receive either 40 mg simvastatin (n = 391) or placebo (n = 412). In the STASH trial, there was also 
no significant reduction of clinical delayed ischemic deficits (64/391 vs 67/412; p = 0.9675) or in-
hospital mortality (34/391 vs 33/412; no p-value given). More recently, Wong et al.[17] in a 
randomized trial of 255 patients, compared 80 mg simvastatin against 40 mg simvastatin daily for 
three weeks and found no difference in the incidence of delayed ischemic deficits (27% vs 24%; p = 
0.586) among the two treatment levels. In contrast to these three studies, a retrospective case 
control study of 278 patients by Sanchez-Peña et al.[18] considered the impact of 40 mg oral 
atorvastatin post-aSAH and concluded atorvastatin reduced the incidence of vasospasm compared 
to control (41/136 vs 61/142; p = 0.027). These studies been interspersed by several smaller 
studies that have demonstrated positive effects of statins. For example, Tseng et al.[19] in a 
randomized trial of 80 aSAH patients showed a 32% reduction (p = 0.006) in incidence of 
vasospasm associated with pravastatin therapy while another contemporaneous randomized trial of 
39 aSAH patients also showed significant reduction in vasospasm in the simvastatin group[20].  
 
Multiple meta-analyses have also investigated the potential benefit of statins in aSAH but have 
reached differing conclusions[21-27]. Two important issues commonly encountered when 
comparing the original studies are the variable choice of statin therapy as well as different dosing 
strategies implemented. While most studies have investigated simvastatin, others have also 
considered pravastatin and atorvastatin. Likewise, a range of doses have been investigated e.g. 
simvastatin from 20 mg up to 80 mg. If not handled appropriately, such heterogeneity may obscure 
a potential benefit of statins that is only seen at higher doses. One recent meta-analysis has 
attempted to account for heterogeneity in dosing by performing subgroup analyses with stratification 
by statin dose[22], and suggested that a reduction in DINDs and mortality was only seen with high-
dose subgroup. As statin dose is quantifiable, an alternative approach is to perform meta-regression 
analysis. By estimating the linear relationship between dose and specified outcomes, meta-
regression is therefore a suitable approach to account for dose-related heterogeneity[28] and 












ACCEPTED MANUSCRIPTregression analysis of randomized and observational studies to investigate whether statin therapy is 
associated with a dose-dependent change in angiographic vasospasm, DINDs or mortality following 
aSAH. Using the estimated meta-regression linear models, we also predict the dose-effect 















Search strategy and study selection 
Articles were searched in Scopus, PubMed and  the Cochrane Central Register of Controlled Trials. 
Search terms included “simvastatin”, “pravastatin”, “atorvastatin”, “statin”, “statins”, “aneurysmal 
subarachnoid hemorrhage”, “aneurysmal subarachnoid hemorrhage”, “vasospasm”, “DIND” and 
“mortality”. Citations and citing articles of the retrieved articles were also screened to identify 
additional relevant studies. Conference abstracts were included in the search. There were no 
language restrictions and studies not in English were translated to English. Articles were last 
searched on the 14th of August 2017.  
 
Inclusion criteria were (1) randomized control trials (RCTs), prospective or retrospective 
observational studies that investigated the effect of statins in aneurysmal subarachnoid 
hemorrhage; (2) study endpoints included at least one of cerebral vasospasm, DIND or mortality. 
Exclusion criteria were (1) studies that investigated the effect of statins in animals; (2) non-
aneurysmal SAH e.g. trauma or arteriovenous malformation rupture; (3) studies investigating the 
effect of long-term statin use, statin treatment investigated prior to SAH. 
 
Data extraction and analysis 
The literature search and data extraction were performed independently by two reviewers (M-ST, S 
Prakash) according to pre-determined study selection criteria. Disagreements were resolved by 
involvement of a third author (SB). Quality assessment of the selected studies was performed using 
the risk of bias tool provided by the Cochrane Collaboration[29]. The following data were extracted: 
first author, year of publication, study design, study size, patient characteristics, subarachnoid 













ACCEPTED MANUSCRIPTOutcomes extracted were vasospasm, DIND and mortality. We required angiographic evidence or 
flow measurements for inclusion of vasospasm data. Absolute risks (ARs) were extracted from the 
number of outcome events in each treatment group. Non-simvastatin therapy doses were converted 
to simvastatin-equivalent doses (Table 1)[30], while placebo or no treatment was assigned a 
simvastatin-equivalent dose of 0 mg. Outcomes were expressed as absolute risk (AR) for a given 
statin dose or control (placebo). Individual study ARs were transformed using Freeman-Tukey 
arcsine square root transformation  → sin 	
+ sin	
. Meta-regression using inverse 
variance weighting and robust variance estimation[31] with small sample adjustment[32] was 
performed to assess the effect of statin dose on transformed AR in a random effects model. The 
sign of the estimated slope coefficients was used to detect a dose-dependent relationship between 
transformed AR and statin dose. Sensitivity analysis of the estimated slope coefficients was 
performed by removing single studies at a time. The dose-dependence of predicted AR with 95% 
confidence interval (CI) was recovered using Miller’s Freeman-Tukey inverse  →  1 −
|cos | 1 − sin  + sin  − 	 /
/ [33]. Tests for the regression coefficients were two-sided 
with a significance level of 0.05. All statistical analyses were performed using Stata/IC 14 (Stata 













ACCEPTED MANUSCRIPTPredicted absolute risk, number needed to treat and study size calculations 
The linear model obtained from meta-regression also allows estimation of absolute risk using the 
Freeman-Tukey inverse. The absolute risk reduction (ARR) can then be calculated as  = !" −
!#, where !" and !# denote the absolute risk at baseline and with a given dose of statin therapy, 
respectively. The number needed to treat (NNT) is therefore $$% = 1/. Finally, the number 
required per group to detect a difference in these estimated absolute risks with power &1 − '( and a 
two-sided significance level α is given by[35]: 
 = )*∝/,2!̅/0 + *1,!"&1 − !"( + !#&1 − !#(&!" − !#( 2
3
, 
where !̅ = 5657  and /0 = 1 − !̅. With a significance level 9 = 0.05 and power 1 − ' = 0.8, we have 















The literature search strategy yielded a total of 18 studies for analysis, which comprised of 
randomized controlled trials (RCTs)[16, 17, 19, 20, 36-43], prospective observational cohort 
studies[15, 44] and retrospective observational studies[18, 45-47]. This represented 2594 patients. 
Two studies were published as abstracts[37, 39]. One study published in Chinese was translated 
into English[42]. Four studies were excluded for their focus on the effect of pre-SAH statin use on 
outcomes[48-51]. The selection of studies is shown in Figure 1A. The quality of the included studies 
was measured by the Cochrane risk of bias assessment tool[29] (Figure 1B). If bias was not 
addressed in the trials, we assumed an unclear risk. Nine studies (50.0%) were randomized control 
trials, with blinding of participants and personnel[16, 17, 19, 20, 36, 38, 40, 41, 43]. Risk of overall 
bias was considered high in 7 studies (39.0%)[15, 37, 39, 42, 44-46], whereas the risk was minimal 















ACCEPTED MANUSCRIPTCharacteristics of eligible studies and study interventions 
Characteristics of patients from included studies are shown in Table 2. The majority of patients were 
female and most underwent surgical clipping or endovascular coiling after presentation. Garg et 
al.[40] included clipped patients only. Clinical severity of aSAH was graded using the WFNS scale in 
10 studies; 27.9% (443/1585) of patients were WFNS grade 4 or higher. Several studies also 
reported Hunt-Hess grade (not shown). Fisher grade was reported in 12 studies; among these 
40.6% (884/2179) patients were grade 4.  
 
Definitions of study outcomes (vasospasm, DIND, mortality) are shown in Table 3 and 
characteristics of study interventions are shown in Table 4. Of the 18 studies, twelve investigated 
simvastatin[15-17, 20, 36, 38-41, 44, 46, 47], three investigated pravastatin[19, 37, 45] two 
investigated atorvastatin[18, 42] while a single study investigated pitavastatin[43]. Simvastatin dose 
ranged from 20 mg to 80 mg daily and atorvastatin ranged from 20 mg to 40 mg daily. Only 40 mg 
of pravastatin daily and 4 mg of pitavastatin daily were investigated. Two studies did not include a 
control/placebo group[17, 44], one of which included three statin treatment groups[44]. One study 
involved a simvastatin and magnesium treatment arm[46], but this arm was excluded from analysis. 
Duration of statin treatment varied but generally did not exceed 21 days except in[16].  
 
Detection of vasospasm relied on transcranial Doppler (TCD) flow measurements in most studies, 
most commonly of the middle cerebral artery (MCA), however different criteria were used including 
maximal or mean flows. The Lindegaard ratio (MCA mean blood flow velocity/extracranial internal 
carotid artery mean blood flow velocity) was utilized in four studies. Angiographic vasospasm was 
not reported in five studies. DIND was reported in all studies except one. Observation of DIND was 
largely clinical. Most studies required a deterioration in Glasgow Coma Score (GCS) of at least two 
points or change in neurological status not attributable to another cause. Mortality was reported in 
all but three studies. Again, the definition of mortality varied between the studies, ranging from in-












ACCEPTED MANUSCRIPTMeta-regression analysis of study outcomes 
We utilized a meta-regression approach to quantify the relationship between aSAH outcomes 
(Table 4) and statin dose (Table 5 and Figure 2). As the Freeman-Tukey arcsine square root 
transformation is nonlinear, the estimated regression coefficients only represent the linear 
relationship for the transformed outcome covariate and dose, whereas the relationship between AR 
and dose is nonlinear after inverse transformation. Applying the Freeman-Tukey transform on the 
proportions of vasospasm and fitting the linear regression on the transformed variable showed that 
higher doses of simvastatin were associated with a lower incidence of vasospasm (p = 0.032). 
Similarly, increasing simvastatin dose was also associated with reduced rates of DIND (p = 0.039) 
and mortality (p = 0.035). However, sensitivity analysis showed that these meta-regression 
outcomes were not strongly robust to exclusion of individual studies. Individual exclusion of 6 out of 
13 studies led to statistically non-significant coefficients for the vasospasm outcome. For DIND this 
figure was 7 out of 17 studies, and for mortality 7 out of 14 studies.  
 
The regression model can be used to predict the dose-dependent AR of the various outcomes 
(Table 6). Inverting the transformed linear regression yields a predicted AR of vasospasm of 43.4% 
(95% CI; 35.8% to 51.1%) at 0 mg simvastatin compared to 26.3% (95% CI; 13.8% to 40.9%) at 80 
mg. Likewise, the predicted AR of DIND of 33.8% (95% CI; 24.7% to 44.4%) at 0 mg simvastatin 
compares to 20.6% (95% CI; 13.4% to 28.7%) at 80 mg. Finally, there is a predicted AR of mortality 
of 16.8% (95% CI; 11.9% to 22.1%) at 0 mg simvastatin compared to 8.4% (95% CI; 3.3% to 
15.2%) at 80 mg. The predicted AR values can then be used to derive predicted ARR and NNT. 
These are shown in Table 6. Finally, the predicted AR can be used to estimate the minimum sample 
sizes required to detect reductions in AR at a significance level of 9 = 0.05 (two-sided) and power 


















The present study provides some evidence that statin therapy is associated with dose-dependent 
reductions in incidence of vasospasm, DIND and mortality following aSAH. Meta-regression 
analysis of Freeman-Tukey transformed proportions does not provide a linear relationship between 
risk of outcome and dose since the transformation is nonlinear. Instead the absolute risk at different 
doses can be estimated post-regression by inverting the transformation on the prediction model 
produced by regression. This approach yielded significant estimated ARR in vasospasm, DIND and 
mortality of 16.4%, 11.6% and 9.5%, respectively, with corresponding NNT of 7, 9 and 11. However, 
sensitivity analysis showed that these findings were not robust to exclusion of individual studies and 
may reflect a high degree of heterogeneity among the studies. 
 
These results need to be taken in context of the findings of previous studies. The studies by 
Sanchez-Peña et al.[18] and Li[42] were the only in our analysis that considered atorvastatin and 
found a positive benefit on the incidence of vasospasm. Whether this benefit was specific to 
atorvastatin or reflects a class effect of statins remains unclear. Our results are also at odds with 
several studies that have not demonstrated significant improvements in outcomes with statin 
therapy. One explanation is that many studies may not have been sufficiently powered to reliably 
detect a difference in outcomes. Related to this, trials that have only utilized a relatively low dose of 
statin may not have produced a detectable difference in outcome. For example, the largest 
randomized trial to date, the STASH trial[16], included 803 patients randomized to 40 mg 
simvastatin treatment with modified Rankin Scale (mRS) at 6 months as the primary outcome. 
Mortality is included in this scale. In Table 6 we include sample size calculations based on dose-
dependent predicted absolute risks. At a simvastatin dose of 40 mg, we note that a substantially 
larger study size of 1830 would be required to detect a reduction in mortality with 80% power. 













ACCEPTED MANUSCRIPTA number of recent meta-analyses have broached the subject of whether statins may be beneficial 
in aSAH but have reached differing conclusions[21-27]. Our sensitivity analysis provides some 
insight into the discrepancies since statistical significance of the meta-regression coefficients was 
sensitive to exclusion of individual studies. The variations in study selection criteria across individual 
meta-analyses is likely to contribute to the lack of consensus among previous meta-analyses.   
 
Our study has several limitations. Our dose equivalence conversion was based on the known 
cholesterol-lowering effects of statins. Whether the same dose conversion applies to their 
pleiotropic effects is less clear. There is some evidence however that this may be the case[52]. 
However, all statins are not created equal and this element is not incorporated into the analysis. On 
the one hand, simvastatin and pravastatin have superior safety and tolerability profiles[53]; on the 
other, simvastatin, atorvastatin and pitavastatin are lipophilic and thus should cross the blood-brain 
barrier to similar extents whereas pravastatin is hydrophilic[54]. Brain metabolism of statins has not 
been studied and it is unclear whether the acid or lactone forms exert neuroprotective effects in the 
brain[50]. We did not analyze the rate of side effects associated with statin therapy, since we found 
this information to be inconsistently reported. Outcomes were analyzed as absolute risk instead of 
relative risk for several reasons. While relative risk measures may be more consistent[55, 56], they 
are relative and require measurement of absolute risk at some baseline, typically placebo or the no-
dose scenario. In contrast, absolute risk is directly related to incidence and importantly, absolute risk 
measures enabled inclusion of studies that were not placebo controlled[17, 44]. Utilization of 
absolute risk and absolute risk reduction also allowed derivation of indices such as number needed 
to treat (Table 6).  
 
We also observed substantial heterogeneity across the studies. This was partly reflected in our 
sensitivity analysis. While we attempted to account for one source, namely dose of statin, we can 
identify several other important sources of heterogeneity that are more difficult to account for by 
meta-regression. These include choice of statin and duration of treatment, since in some studies, 












ACCEPTED MANUSCRIPTprospective and retrospective observational studies. Randomized controlled studies typically 
impose stricter inclusion criteria and consequently may exclude the most ill patients who, at the 
same time, would also derive the greatest benefit from therapy. For example, Garg et al. excluded 
Hunt and Hess Grade V aSAH[40] and thus their findings may not generalize to all aSAH patients. 
Conversely, exclusion criteria may also limit patients with comorbidities such as hepatic, renal or 
other systemic disease, and it is these patients who are also more vulnerable to side effects of 
therapy. Taken together, it can be argued that observational studies include patients more 
representative of the typical population at risk[57].  
 
Definitions of DIND varied across studies as did criteria for establishing the presence of vasospasm. 
Many of the studies required a new onset reduction in GCS, while some also relied on radiologic 
evidence of ischemia to confirm DIND. TCD was a widely-adopted modality for confirming 
vasospasm, but velocity thresholds differed between studies as well as whether peak or mean 
velocities were utilized. In contrast, mortality was simpler to establish, but follow-up duration varied; 
mortality “at discharge” was frequently but not universally adopted. These differences may arise 
from institution-specific practices or resource limitations. Moreover, such inconsistencies present 
challenges to comparing studies by contributing to heterogeneity. We therefore highlight a need to 
establish uniform definitions of these outcomes to enable direct comparisons of future studies and 
evaluate the efficacy of interventions more effectively. One such definition for delayed ischemia has 
been proposed[58].  
 
Meta-regression analysis is hypothesis generating and provides some guidance on future studies 
and appropriate dosing strategies. The adverse effects of high-dose strategies must be weighed 
against the potential benefits of statin therapy on the devastating sequelae of aSAH. However, the 
side effects profile of statins is well-known and has been extensively explored[53, 59]. Importantly, 
even high-dose 80 mg atorvastatin daily is only associated with a relatively low risk of serious 












ACCEPTED MANUSCRIPTare advantageous in the design of studies and may enable anticipation or mitigation of potential 




Statin therapy is associated with dose-dependent reductions in incidence of vasospasm, DIND and 
mortality following aSAH. We do not recommend changing current practice on the basis of our 
meta-regression analysis. On the other hand, these results provide guidance for the design of future 
studies and support further exploration of high-dose strategies.  
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ACCEPTED MANUSCRIPTFigure 1: Study identification and risk of bias. (A) PRISMA flow diagram showing steps to selection 
of relevant studies for meta-regression analysis. (B) Risk of bias assessment. Shading represents 
degree of bias (green, low risk; yellow, unclear risk; red, high risk). 
 
Figure 2: Meta-regression analysis of the effect of statin dose on outcomes. Outcomes shown are 
vasospasm (A,B; green), DIND (C,D; red) and mortality (E,F; blue). (A,C,E) Meta-regression of 
individual studies (grey lines) produces a linear estimate of the Freeman-Tukey transformed risk of 
outcome versus dose relationship (colored line). (B,D,F) The estimated linear estimates were 
inverted to provide the absolute risk of outcome at different statin doses (colored line). Individual 
intervention groups are shown (black dots). Grey shading indicates 95% confidence interval of the 
estimates.  
 













Table 1 – Simvastatin equivalent dosing 
Simvastatin  Pravastatin  Atorvastatin  Pitavastatin  
10 mg 20 mg - 1 mg 
20 mg 40 mg 10 mg 2 mg 
40 mg 80 mg 20 mg 4 mg 
















Table 2 – Study and patient characteristics 











grade ≥ 4 Clip Coil 
Lynch et al, 200520 RCT 39 56 ± 15 33 (85) - 2 17 22 
Tseng et al, 200519 RCT 80 53 ± 12 44 (55) 26 - 52 13 
Chou et al, 200836 RCT 39 53 ± 13 29 (75) - 0 33 6 
Jaschinski et al, 
200837 
RCT 98 - - - - 42 24 
Kerz et al, 200846 ROS 72 55 (47 – 64) 43 (60) 24 46 18 20 
Kramer et al, 200847 ROS 150 55 (53 – 59) 104 (69) 48 46 80 65 
Kern et al, 200945 ROS 130 56 ± 14 64 (49) 33 46 50 67 
McGirt et al, 200915 POS 340 53 ± 13 256 (75) - 125 175 65 
Vergouwen et al, 
200938 RCT 32 53 ± 11 20 (63) 8 - 7 24 
Li, 201042 RCT 47 - 21 (45) - - - - 
Macedo et al, 201039 RCT 20 - - - - - - 
Sanchez-Peña et al, 
201218 ROS 278 53 ± 14 178 (64) - 79 47 231 
Garg et al, 201340 RCT 38 49 ± 9 17 (45) 1 0 38 0 
Kirkpatrick et al, 
201416 RCT 803 50 ± 10 551 (69) 184 406 254 513 
Wong et al, 201517 RCT 255 57 ± 10 165 (65) 109 73 133 101 
Woo et al, 201544 POS 87 55 ± 12 62 (71) - 54 61 26 
Diringer et al, 201641 RCT 25 60 ± 11 16 (64) 10 7 - - 
Naraoka et al, 201743 RCT 108 58 ± 11  74 (69) - - 99 9 
POS, prospective observational study; ROS, retrospective observational study; RCT, randomized control study; SD, standard 














Table 3 – Study outcome definitions 
Study, year Vasospasm DIND Mortality 
Lynch et al, 
200520 
Angiographic or TCD (VMCA 
> 160 m/s) in conjunction 
with DIND 
Clinical impression of DIND (unrelated to rebleed, 
hydrocephalus, or infection) with confirmatory 
radiography 
Not defined 
Tseng et al, 
200519 
TCD (VMCA > 120 cm/s, LR 
> 3) 
Development of focal neurological deficits or drop in 
GCS ≥ 2 points 
At discharge 
Chou et al, 
200836 
TCD (peak systolic MCA 
flow velocity > 200 cm/s, 
LR > 3); 23 (59%) 
Drop in modified GCS ≥ 2 points or unaccountable new 




- Not defined 
ICU mortality 
 
Kerz et al, 
200846 
- 
Drop in GCS ≥ 2 points, new focal deficit or TCD mean 
flow velocity of > 120 cm/s or increase > 50 cm/s on 2 
consecutive days 
14 day in-hospital 
mortality 
Kramer et al, 
200847 
Radiographic vasospasm 
(> 33% narrowing) on CT 
or catheter angiography 
 
Change in neurological status not attributable to another 
cause (e.g. seizure, hydrocephalus, recent sedation, or 
metabolic derangement) with at least moderate 
radiographic vasospasm 
At discharge or 6-
week follow-up 
 
Kern et al, 
200945 
TCD (VMCA > 120 cm/s, LR 
> 3) 
Focal neurological deficits not explained by 
hydrocephalus, surgical trauma, or new hemorrhage 
In-hospital 
mortality  
McGirt et al, 
200915 
- 
Change in neurological status not attributable to another 
cause (e.g. seizures, hydrocephalus, recent sedation, 
repeat hemorrhage, clip-induced infarct, or metabolic 
derangement) 
Death within 28 
days of admission 
Vergouwen 
et al, 200938 
TCD (VMCA or VACA ≥ 120 
cm/sec) 
Gradual deterioration with focal neurologic 
impairment and/or a drop in GCS ≥ 2 points 
Death on GOS at 
3 months 
Li, 201042 TCD (VMCA > 120 cm/s) 
Vasospasm together with delayed neurological 
impairment not due to another cause (e.g. bleeding, 





Altered neurological signals in presence of changes 





Peña et al, 
201218 
Vessels assessed on 
angiogram showing the 
most severe abnormalities 
 
- - 
Garg et al, 
201340 
TCD (maximal MCA 
velocity ≥ 160 cm/sec at 
any point of time within 14 
days) 
New ischemic neurological deficits in 1st 2 weeks after 
ictus not attributable to other causes 
Not defined 
Kirkpatrick 
et al, 201416 
- 
Deterioration in GCS ≥ 2 points not be attributable to 
any other cause including sepsis 
Mortality at 6 
months 
Wong et al, 
201517 
- 
Drop in GCS ≥ 2 points or new focal neurological deficit 
last more than 2 hours 
Death on mRS at 
3 months 
Woo et al, 
201544 
TCD (highest VMCA > 150 
cm/s in single test, change 
in highest VMCA > 50 cm/s 
in serial test, or LR > 3) 















Angiography, moderate or 
severe vasospasm of distal 
segments of the ACA, 
MCA, and PCA 
New focal deficit or global decline in consciousness after 
exclusion of other causes of neurological deterioration 




Angiographic (DSA), ≥ 
25% decrease in arterial 
wall diameter compared to 
baseline DSA 
New focal, neurological deficits or drop in GCS ≥ 2 
points 
- 
CT, Computed tomography; DSA, Digital subtraction angiography; GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Score, LR; 
Lindegaard ratio (middle cerebral artery mean blood flow velocity/extracranial internal carotid artery mean blood flow velocity); mRS, 
modified Rankin Scale; TCD, transcranial Doppler; ACA, anterior cerebral artery; MCA, middle cerebral artery; VMCA/ACA, MCA/ACA 














Table 4 – Study interventions and outcomes by simva statin equivalent dose 














































































































At least 14 
days 
- 52 43 
26 
31 






























































21 days or 
until 
discharge 
- 67 64 
35 
37 








































































Coefficient SE 95% CI p-value 




DIND 17 2363 -0.00316 0.00138 (-0.00586,  -0.00047) 0.0392 


















Table 6 – Predicted absolute risk of adverse outcom es associated with statins 
Outcome Dose AR 95% CI ARR NNT Study size  
Vasospasm  
0 mg 47.2% 40.1% to 54.4% - - - 
20 mg 43.0% 35.5% to 50.8% 4.2% 24 6872 
40 mg 38.9% 29.6% to 48.6% 8.3% 13 1380 
80 mg 30.9% 17.3% to 46.2% 16.4% 7 360 
DIND 
0 mg 32.0% 23.3% to 41.3% - - - 
20 mg 28.9% 22.2% to 36.1% 3.0% 33 8902 
40 mg 26.0% 20.4% to 32.0% 6.0% 17 2254 
80 mg 20.4% 14.1% to 27.4% 11.6% 9 580 
Mortality 
0 mg 16.6% 11.4% to 22.5% - - - 
20 mg 14.0% 9.9% to 18.6% 2.6% 38 7211 
40 mg 11.5% 7.5% to 16.1% 5.1% 20 1830 
80 mg 7.1% 2.3% to 13.9% 9.5% 11 482 























Records after duplicates removed
(n = 311)
Titles and abstracts screened
(n = 311)
Full-text articles or abstracts
assessed for eligibility
(n = 27) 




- Protocol (n = 2)
- Shared population (n = 2)
- Irrelevant focus (n = 1)
- Irrelevant outcomes (n = 3)
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